FDA approves first nasal spray flu vaccine for use at home
The Food and Drug Administration on Friday approved the first at-home flu vaccine, a nasal spray that consumers with a ...
FDA approves at-home flu vaccine
The FDA is clearing the way for an at-home flu vaccines. A self-administered version of pharmaceutical giant AstraZeneca’s ...
FDA approves first self-administered flu vaccine spray
The Food and Drug Administration announced Friday it had broadened the approval of the FluMist nasal spray to become the ...
US FDA approves AstraZeneca's self-administered nasal spray flu vaccine
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for ...
Nasal Flu Vaccine Is Approved for At-Home Use
The F.D.A. authorized AstraZeneca’s treatment to be given outside a health care setting, although it will still need a ...
FDA approves first flu vaccine that can be self-administered at home
The US Food and Drug Administration on Friday approved the first flu vaccine that does not have to be administered by a ...
US FDA approves AstraZeneca's flu vaccine for self-administration
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for ...
Missouri health worker who had contact with bird flu patient develops symptoms, US officials report
Missouri healthcare worker who had contact with a hospitalized patient infected with bird flu developed mild respiratory ...
FDA approves ‘FluMist,' says no healthcare provider needed
FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the ...
FDA approves first self-administered flu vaccine
The Food and Drug Administration (FDA) announced Friday it has approved the first flu vaccine that can be self-administered, ...
AstraZeneca falls Friday, still outperforms market
AstraZeneca PLC AZN shares inched down 0.99% to £117.80 Friday, on what proved to be an all-around rough trading session for ...
AstraZeneca: Poised for Growth with Promising Innovation Pipeline and Attractive Valuation
In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on AstraZeneca (AZN – Research Report), with a ...